Previous 10 | Next 10 |
The opioid epidemic is a complex problem with no simple or ideal solution. The Centers for Disease Control and Prevention (CDC) estimates that 47,600 Americans died from opioid-related overdoses in 2017. One study published earlier this year by Massachusetts General Hospital estimates that 700,0...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that data from studies of YUPELRI ® (r...
Allergan (NYSE: AGN ) resumed with Market Perform rating and $180 (7% upside) price target at Bernstein. More news on: Allergan plc, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Global companies' performance on environmental, social, and governance ((ESG)) issues is rapidly becoming more critical to their competitiveness, profitability and share price. We are writing this commentary and re-orienting our own investment philosophy, because we profoundly care about envir...
If you're looking for solid dividend stocks , big drugmakers are a good place to start. And among the big drug stocks, few offer dividends as attractive as those of Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) . Of course, in buying stocks, there's more to the story than just d...
Pfizer (NYSE: PFE) is America's largest pharmaceutical company, but it's about to become a lot smaller. A narrow focus could lead to explosive growth, but it won't make cash flows any more predictable. Will Pfizer give investors the earnings growth they desire, or should they prepare for tr...
HERTFORDSHIRE, England , and PITTSBURGH , Sept. 27, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission ("SEC"). On July 29, 2019 , the Company disclosed in its ...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Combining several ratios, biotechnology looks underpriced by about 30% relative to ...
HERTFORDSHIRE, England and PITTSBURGH , Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex ® Injection. ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...